NFE2L2 and sarcoma: Because previous reports showed that NRF2 can inhibit the EMT process after damage to lungs, the absence of NRF2 protein expression in the CPN sarcomas may indicate a requirement for its silencing to allow tumor progression, likely though an epigenetic mechanism (58, 59).